299 related articles for article (PubMed ID: 17910610)
1. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
Saario SM; Laitinen JT
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):287-93. PubMed ID: 17910610
[TBL] [Abstract][Full Text] [Related]
2. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
Fezza F; De Simone C; Amadio D; Maccarrone M
Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
Myllymäki MJ; Saario SM; Kataja AO; Castillo-Melendez JA; Nevalainen T; Juvonen RO; Järvinen T; Koskinen AM
J Med Chem; 2007 Aug; 50(17):4236-42. PubMed ID: 17665899
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of fatty acid amide hydrolase and monoacylglycerol lipase shares discriminative stimulus effects with Δ9-tetrahydrocannabinol in mice.
Hruba L; Seillier A; Zaki A; Cravatt BF; Lichtman AH; Giuffrida A; McMahon LR
J Pharmacol Exp Ther; 2015 May; 353(2):261-8. PubMed ID: 25711338
[TBL] [Abstract][Full Text] [Related]
7. CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay.
Muccioli GG; Labar G; Lambert DM
Chembiochem; 2008 Nov; 9(16):2704-10. PubMed ID: 18855964
[TBL] [Abstract][Full Text] [Related]
8. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
Minkkilä A; Myllymäki MJ; Saario SM; Castillo-Melendez JA; Koskinen AM; Fowler CJ; Leppänen J; Nevalainen T
Eur J Med Chem; 2009 Jul; 44(7):2994-3008. PubMed ID: 19232787
[TBL] [Abstract][Full Text] [Related]
9. Hydrolysis of prostaglandin glycerol esters by the endocannabinoid-hydrolyzing enzymes, monoacylglycerol lipase and fatty acid amide hydrolase.
Vila A; Rosengarth A; Piomelli D; Cravatt B; Marnett LJ
Biochemistry; 2007 Aug; 46(33):9578-85. PubMed ID: 17649977
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid system: An overview of its potential in current medical practice.
Mouslech Z; Valla V
Neuro Endocrinol Lett; 2009; 30(2):153-79. PubMed ID: 19675519
[TBL] [Abstract][Full Text] [Related]
11. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system: current pharmacological research and therapeutic possibilities.
Jonsson KO; Holt S; Fowler CJ
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):124-34. PubMed ID: 16445584
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
Kinsey SG; O'Neal ST; Long JZ; Cravatt BF; Lichtman AH
Pharmacol Biochem Behav; 2011 Mar; 98(1):21-7. PubMed ID: 21145341
[TBL] [Abstract][Full Text] [Related]
14. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields.
Myllymäki MJ; Käsnänen H; Kataja AO; Lahtela-Kakkonen M; Saario SM; Poso A; Koskinen AM
Eur J Med Chem; 2009 Oct; 44(10):4179-91. PubMed ID: 19539407
[TBL] [Abstract][Full Text] [Related]
15. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
16. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
Vandevoorde S; Lambert DM
Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
[TBL] [Abstract][Full Text] [Related]
17. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
Pertwee RG
Proc Nutr Soc; 2014 Feb; 73(1):96-105. PubMed ID: 24135210
[TBL] [Abstract][Full Text] [Related]
18. The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.
Fowler CJ
Handb Exp Pharmacol; 2015; 231():95-128. PubMed ID: 26408159
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.
Saario SM; Poso A; Juvonen RO; Järvinen T; Salo-Ahen OM
J Med Chem; 2006 Jul; 49(15):4650-6. PubMed ID: 16854070
[TBL] [Abstract][Full Text] [Related]
20. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
